MA41781B1 - Combination therapy with a tlr7 agonist and a hepatitis b virus capsid assembly inhibitor - Google Patents
Combination therapy with a tlr7 agonist and a hepatitis b virus capsid assembly inhibitorInfo
- Publication number
- MA41781B1 MA41781B1 MA41781A MA41781A MA41781B1 MA 41781 B1 MA41781 B1 MA 41781B1 MA 41781 A MA41781 A MA 41781A MA 41781 A MA41781 A MA 41781A MA 41781 B1 MA41781 B1 MA 41781B1
- Authority
- MA
- Morocco
- Prior art keywords
- hepatitis
- combination therapy
- tlr7 agonist
- capsid assembly
- assembly inhibitor
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 229940124615 TLR 7 agonist Drugs 0.000 title abstract 2
- 210000000234 capsid Anatomy 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des compositions et des méthodes pour traiter une infection par le virus de l'hépatite b. En particulier, la présente invention porte sur une thérapie combinée comprenant l'administration d'un agoniste de tlr7 et d'un inhibiteur d'assemblage de capside du vhb à utiliser dans le traitement d'un patient atteint d'hépatite b chronique.The present invention provides compositions and methods for treating infection with hepatitis b virus. In particular, the present invention relates to a combination therapy comprising the administration of a tlr7 agonist and a vhb capsid assembly inhibitor for use in the treatment of a patient with chronic hepatitis b.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015074269 | 2015-03-16 | ||
| PCT/EP2016/055484 WO2016146598A1 (en) | 2015-03-16 | 2016-03-15 | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41781B1 true MA41781B1 (en) | 2020-07-29 |
Family
ID=59256523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41781A MA41781B1 (en) | 2015-03-16 | 2016-03-15 | Combination therapy with a tlr7 agonist and a hepatitis b virus capsid assembly inhibitor |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR103925A1 (en) |
| MA (1) | MA41781B1 (en) |
-
2016
- 2016-03-14 AR ARP160100671A patent/AR103925A1/en unknown
- 2016-03-15 MA MA41781A patent/MA41781B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR103925A1 (en) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001433A1 (en) | Modulators of the core protein of hepatitis b. (divisional request 201800684) | |
| MX2022011756A (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor. | |
| MA39721A (en) | NEW CONDENSED HETEROARYLDIHYDROPYRIMIDINES IN POSITION 6 FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | |
| MX2021014771A (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EA201890571A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIOLATION ASSOCIATED WITH THE PROTROTYNCONVERTASE GENE SUBTILYSINE / CEXINOUS TYPE (PCSK9) | |
| MA40843A (en) | HEPATITIS DELTA VIRUS RNAI COMPOSITIONS AND METHODS FOR USING THEM | |
| MX2017015574A (en) | Inhibitors of bruton's tyrosine kinase. | |
| MA34002B1 (en) | ANTIVIRAL THERAPY | |
| EA201990951A1 (en) | COMBINATIONS CONTAINING SSAO / VAP-1 INHIBITOR AND SGLT2 INHIBITOR, AND THEIR APPLICATION | |
| MA38406A1 (en) | Newcastle disease virus and their uses | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MA39725B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2019005401A (en) | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof. | |
| EA201691555A1 (en) | METHODS OF TREATMENT AND PREVENTION OF KIDNEY DISEASES AND LIVER FATIAL DYSTROPHIES | |
| EP3402480A4 (en) | COMPOSITIONS AND METHODS FOR INTRAVENOUS DELIVERY OF 2-BROMO-1- (3,3-DINITROAZETIDIN-1-YL) ETHANONE | |
| EA201990424A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| MX2016011667A (en) | Topical compositions comprising extract of coriolus versicolor for autoimmunity enhancement. | |
| EA201990428A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| EP3496743A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ARGININ DEPLETION CANCER USING IMMUNOONCOLOGY AGENTS | |
| EP3641746A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION | |
| EA201991175A1 (en) | THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS | |
| MX2022001261A (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases. | |
| MX389282B (en) | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES. | |
| MA39228A1 (en) | Compositions for use in treating allergic conditions |